Form D · Biotechnology
Galavant Therapeutics, Inc.
Menlo Park, CA · CIK 0001808255
Offering snapshot reported Apr 1, 2020 · SEC filing
- Reported sold
- $100K Offering amount: $100K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 20, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 1, 2020 | Initial | $100,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-364151
Source: Form D, filed Apr 1, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Seth Harrison | Director |
| Jonathan Waldstreicher | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
155 Jefferson Drive, Suite 100
Menlo Park, CA, 94025
Menlo Park, CA, 94025